Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 1277Carcinoma, Non-Small-Cell Lung 926Prostatic Neoplasms 729Neoplasms 632Multiple Myeloma 553Lymphoma 539Colorectal Neoplasms 529Lung Neoplasms 515Leukemia 497Leukemia, Myeloid, Acute 472Neoplasm Metastasis 470Melanoma 425Lymphoma, Non-Hodgkin 417Ovarian Neoplasms 416Leukemia, Lymphocytic, Chronic, B-Cell 386Pancreatic Neoplasms 373Recurrence 335Precursor Cell Lymphoblastic Leukemia-Lymphoma 327Head and Neck Neoplasms 306Lymphoma, Large B-Cell, Diffuse 294Glioblastoma 294Myelodysplastic Syndromes 287Brain Neoplasms 287Lymphoma, Follicular 286Stomach Neoplasms 280Carcinoma, Renal Cell 268Hodgkin Disease 261Carcinoma, Hepatocellular 261Rectal Neoplasms 256Sarcoma 250

Interventions

sipuleucel-T 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Completed × Metastatic Castrate-resistant Prostate Cancer × Clear all
NCT01818986 2022-05-06

Sipuleucel-T and Stereotactic Ablative Body Radiation (SABR) for Metastatic Castrate-resistant Prostate Cancer (mCRPC)

University of Texas Southwestern Medical Center

Phase 2 Completed
20 enrolled 13 charts
Genitourinary

Metastatic Castrate-resistant Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡